Ferriprox 1000mg film-coated tablets
*Company:
Chiesi LimitedStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 18 October 2022
File name
Ferriprox 1000mg FCT PIL CP0072-3_NI-IE.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
Free text change information supplied by the pharmaceutical company
Pregnancy and breast-feeding
Ferriprox may cause harm to unborn babies when used by pregnant women. Ferriprox must not be used during pregnancy unless clearly necessary. If you are pregnant or you become pregnant during treatment with Ferriprox, get medical advice immediately.
Both female and male patients are recommended to take special precautions in their sexual activity if there is any possibility for pregnancy to occur: Women of childbearing potential are recommended to use effective contraception during treatment with Ferriprox and for 6 months after the last dose. Men are recommended to use effective contraception during treatment and for 3 months after the last dose. This should be discussed with your doctor.
Do not use Ferriprox if you are breast-feeding. Please refer to the patient card attached to the carton.
Updated on 18 October 2022
File name
Ferriprox FCT SmPC EU_CS0111-3.pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.6 Fertility, pregnancy and lactation
Women of childbearing potential/contraception in men and women
Due to the genotoxic potential of deferiprone (see section 5.3), women of childbearing potential are recommended use effective contraceptive measures and avoid becoming pregnant while being treated with Ferriprox and for 6 months following the completion of treatment.
Men are recommended to use effective contraceptive measures and to not father a child while receiving Ferriprox and for 3 months following completion of treatment.
Updated on 14 January 2022
File name
Ferriprox FCT 1000mg PIL - UK(NI) + IE.pdf
Reasons for updating
- Change to packaging
Free text change information supplied by the pharmaceutical company
Text of the patient card moved from the leaflet to the outer box
Updated on 14 January 2022
File name
Ferriprox FCT SmPC EU_CS0111-2.pdf
Reasons for updating
- Correction of spelling/typing errors
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 01 October 2020
File name
Ferriprox 1000mg FCT EU_CP0072-1.pdf
Reasons for updating
- New PIL for new product
Updated on 01 October 2020
File name
Ferriprox FCT EU_CS0111-1.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)